Dr. Richardson - An Overview of Studies of the New Agent Perifosine (KRX-0401) Alone and in Combination for Patients with Relapsed/Refractory Multiple Myeloma
Paul Richardson, MD Jerome Lipper Myeloma Center Dana Farber Cancer Institute Boston, MA Member, IMF Board of Scientific Advisors
back
print
related articles
Be the first to comment